Compare BLTE & SXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | SXT |
|---|---|---|
| Founded | 2018 | 1882 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.7B |
| IPO Year | 2021 | 1994 |
| Metric | BLTE | SXT |
|---|---|---|
| Price | $161.06 | $134.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $198.00 | $121.00 |
| AVG Volume (30 Days) | 153.2K | ★ 445.2K |
| Earning Date | 05-08-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | N/A | ★ 7.48 |
| EPS | N/A | ★ 2.24 |
| Revenue | N/A | ★ $1,396,499,000.00 |
| Revenue This Year | N/A | $8.99 |
| Revenue Next Year | $492.11 | $9.45 |
| P/E Ratio | ★ N/A | $59.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $62.18 | $82.60 |
| 52 Week High | $200.00 | $136.58 |
| Indicator | BLTE | SXT |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 64.77 |
| Support Level | $158.32 | $109.48 |
| Resistance Level | $172.02 | N/A |
| Average True Range (ATR) | 6.82 | 3.35 |
| MACD | -0.74 | 0.18 |
| Stochastic Oscillator | 27.85 | 81.06 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are: Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.